MedTrace Logo

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2017-03-13

No results posted yet for this study

Summary

RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably.

PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

Conditions

  • Ototoxicity
  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

PROCEDURE

management of therapy complications

Undergo hearing tests

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Lillian Sung, MD, PhD · The Hospital for Sick Children

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2015-01-31
Completion
2017-02-28

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458887 on ClinicalTrials.gov